
FibroBiologics, Inc.
$0.78
+0.0095 (1.23%)
Latest News
FibroBiologics Granted Extension by Nasdaq to Regain Compliance
Feb 23, 2026 08:30 AM
FibroBiologics' Chairman & CEO Pete O'Heeron Selected to Present at A4LI's H-SPAN Summit at Georgetown University
Feb 10, 2026 08:30 AM
FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia
Feb 05, 2026 08:30 AM
FibroBiologics to Present at the DealFlow Discovery Conference
Jan 20, 2026 08:30 AM
FibroBiologics CEO Issues Letter to Shareholders
Jan 07, 2026 08:30 AM
FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference
Jan 06, 2026 08:30 AM
FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease
Jan 05, 2026 08:30 AM
FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis
Dec 31, 2025 08:30 AM
FibroBiologics Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Dec 16, 2025 04:05 PM
FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Dec 15, 2025 08:00 AM
Sign Up For FBLG Email News Alerts
Disclosure
RedChip Companies, Inc. research reports, company profiles, and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that RedChip Companies Inc. is an investor relations firm hired by certain companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles, or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and/or the Ontario Securities Commission (“OSC”) at www.osc.gov.on.ca.
FibroBiologics (FBLG) is a client of RedChip Companies. FBLG agreed to pay RedChip a $10,000 monthly cash fee, beginning in June 2025, for three months of investor awareness services. FBLG also agreed to pay RedChip a one-time $50,000 fee for a national TV ad campaign aired August 26 to September 9, 2024, a one-time $45,000 fee for a 10-day national TV ad campaign aired October 30 to November 12, 2024, a one-time $37,500 fee for a 10-day national TV ad campaign aired January 30 to February 12, 2025, and a one-time $50,000 fee for a 10-day national TV ad campaign aired April 14 to April 25, 2025.
Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services.